Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions

Expert Opinion on Biological Therapy

Volumn 11, Issue 2, 2011, Pages 235-246

  Parikh, Devang ^a   Juergens, Craig P ^a,b  

^a LIVERPOOL HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

abciximab; acute coronary syndromes; review; thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; C7E3 FAB; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIAC PATIENT; DRUG BINDING SITE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HUMAN; LUNG HEMORRHAGE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANTIBODIES, MONOCLONAL; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MURINAE;

EID: 78651364949     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.551113     Document Type: Article

References (40)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9
2. Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003;3:175-80
3. Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest 1997;100:1-5
4. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-31
5. Wagner CL, Mascelli MA, Neblock DS, et al Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907-14
6. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-8
7. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-91
8. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-44
9. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003;15:71-80
10. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002;106:379-85
11. Investigators TE. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61
12. Investigators TE. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96
13. The CAPTURE Study. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997;349:1429-35
14. Lincoff AM, Califf RM, Moliterno DJ, et al; Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999;341:319-27
15. Mehilli J, Kastrati A, Schuhlen H, et al Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-35
16. Wijns W, Kolh P, Danchin N, et al Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-55
17. Roffi M, Chew DP, Mukherjee D, et al Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-71
18. Montalescot G, Barragan P, Wittenberg O, et al Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903
19. Brener SJ, Barr LA, Burchenal JE, et al Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41
20. Stone GW, Grines CL, Cox DA, et al Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66
21. Mehilli J, Kastrati A, Schulz S, et al Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009;119:1933-40
22. Kushner FG, Hand M, Smith SC Jr, et al 2009 focused updates: ACC/ AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41
23. Zeymer U, Margenet A, Haude M, et al Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J Am Coll Cardiol 2010;56:463-9
24. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97
25. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24
26. Thiele H, Schindler K, Friedenberger J, et al Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118:49-57
27. Romagnoli E, Burzotta F, Trani C, et al Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 2005;105:250-5
28. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 2010;22:278-82
29. Prati F, Capodanno D, Pawlowski T, et al Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 2010;3:928-34
30. Bertrand OF, De Larochelliere R, Rodes-Cabau J, et al A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006;114:2636-43
31. Choussat R, Black A, Bossi I, et al Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade. Comparison of transradial vs transfemoral arterial access. Eur Heart J 2000;21:662-7
32. Marmur JD, Poludasu S, Agarwal A, et al Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18:521-6
33. Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv 2009;73:214-21
34. Cho L, Topol EJ, Balog C, et al Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender. Pooled analysis from EPIC, EPILOG, and EPISTENT trials. J Am Coll Cardiol 2000;36:381-6
35. Philippe F, Larrazet F, Meziane T, Dibie A. Comparison of transradial vs. transfemoral approach in the treatment of acute myocardial infarction with primary angioplasty and abciximab. Catheter Cardiovasc Interv 2004;61:67-73
36. Dasgupta H, Blankenship JC, Wood GC, et al Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140:206-11
37. Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97:426-9
38. Conley M, Patino G, Romick B, et al Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention. Can J Cardiol 2008;24:149-51
39. Tcheng JE, Kereiakes DJ, Lincoff AM, et al Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-5
40. Boersma E, Harrington RA, Moliterno DJ, et al Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98